The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Celyad Oncology SA(NASDAQ:CYAD) 
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical t...
Website: http://www.celyad.com
Founded: 2004
Full Time Employees: 105
Sector: Healthcare
Industry: Biotechnology
Celyad Oncology SA Days Receivable Outstanding ttm (DSO)
Celyad Oncology SA Op Cashflow Per Share ttm
Celyad Oncology SA Free Cashflow Per Share ttm
Celyad Oncology SA Cash Per Share ttm
Celyad Oncology SA P/S ratio ttm
Celyad Oncology SA (GAAP) P/E ratio ttm
Celyad Oncology SA P/B ratio ttm
No extra charts and metrics for this ticker.